Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis

Linezolid is used off-label to treat multidrug-resistant tuberculosis (MDR-TB) in absence of systematic evidence. We performed a systematic review and meta-analysis on efficacy, safety and tolerability of linezolid-containing regimes based on individual data analysis. 12 studies (11 countries from t...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The European respiratory journal Jg. 40; H. 6; S. 1430
Hauptverfasser: Sotgiu, Giovanni, Centis, Rosella, D'Ambrosio, Lia, Alffenaar, Jan-William C, Anger, Holly A, Caminero, Jose A, Castiglia, Paolo, De Lorenzo, Saverio, Ferrara, Giovanni, Koh, Won-Jung, Schecter, Giesela F, Shim, Tae S, Singla, Rupak, Skrahina, Alena, Spanevello, Antonio, Udwadia, Zarir F, Villar, Miquel, Zampogna, Elisabetta, Zellweger, Jean-Pierre, Zumla, Alimuddin, Migliori, Giovanni Battista
Format: Journal Article
Sprache:Englisch
Veröffentlicht: England 01.12.2012
Schlagworte:
Acetamides - pharmacology
Adolescent
Adult
Antitubercular Agents - pharmacology
Extensively Drug-Resistant Tuberculosis - drug therapy
Female
Humans
Linezolid
Male
Middle Aged
Oxazolidinones - pharmacology
Patient Safety
Sputum - metabolism
Treatment Outcome
Tuberculosis, Multidrug-Resistant - drug therapy
ISSN:1399-3003, 1399-3003
Online-Zugang:Weitere Angaben
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Linezolid is used off-label to treat multidrug-resistant tuberculosis (MDR-TB) in absence of systematic evidence. We performed a systematic review and meta-analysis on efficacy, safety and tolerability of linezolid-containing regimes based on individual data analysis. 12 studies (11 countries from three continents) reporting complete information on safety, tolerability, efficacy of linezolid-containing regimes in treating MDR-TB cases were identified based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Meta-analysis was performed using the individual data of 121 patients with a definite treatment outcome (cure, completion, death or failure). Most MDR-TB cases achieved sputum smear (86 (92.5%) out of 93) and culture (100 (93.5%) out of 107) conversion after treatment with individualised regimens containing linezolid (median (inter-quartile range) times for smear and culture conversions were 43.5 (21-90) and 61 (29-119) days, respectively) and 99 (81.8%) out of 121 patients were successfully treated. No significant differences were detected in the subgroup efficacy analysis (daily linezolid dosage ≤ 600 mg versus >600 mg). Adverse events were observed in 63 (58.9%) out of 107 patients, of which 54 (68.4%) out of 79 were major adverse events that included anaemia (38.1%), peripheral neuropathy (47.1%), gastro-intestinal disorders (16.7%), optic neuritis (13.2%) and thrombocytopenia (11.8%). The proportion of adverse events was significantly higher when the linezolid daily dosage exceeded 600 mg. The study results suggest an excellent efficacy but also the necessity of caution in the prescription of linezolid.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ObjectType-Undefined-4
ISSN:1399-3003
1399-3003
DOI:10.1183/09031936.00022912